Dark

Check out our Dark Pool Levels

ACHFF
ARCH BIOPARTNERS INC ORD
stock OTC

EOD

Jul 8, 2025

1.23USD-1.600%(-0.02)21,521

Pre-market

0.00USD-100.000%(-1.25)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 4, 2022

07:25AM EST Research Ethics Board approves amendment to Canadian Treatments GlobeNewswire Inc

Dec 3, 2021

09:51AM EST ACHFF: Arch Biopartners Tackles Life-Threatening Covid Symptoms Benzinga

Dec 1, 2021

07:35AM EST Arch Biopartners Lead Drug LSALT Peptide to GlobeNewswire Inc

Aug 5, 2021

06:30AM EDT Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide GlobeNewswire Inc

Jul 14, 2021

07:00AM EDT Arch Scientists Awarded CIHR Grant to Study LSALT for the GlobeNewswire Inc

Jun 10, 2021

07:20AM EDT Arch Biopartners Files New Patent Application for Novel Antibody GlobeNewswire Inc

May 4, 2021

07:00AM EDT Arch Biopartners Completes Enrollment in Phase II Trial of GlobeNewswire Inc

Apr 15, 2021

07:00AM EDT Arch Biopartners Enters into Worldwide License Agreement with GlobeNewswire Inc

Mar 30, 2021

07:57AM EDT Turkish Ministry of Health Approves Increase in Patient GlobeNewswire Inc

Mar 24, 2021

08:26AM EDT Arch Biopartners Inc. (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive agreement with the University of Cincinnati (UC) to license new patent claims for an AB569 topical wound application designed to prevent, treat and heal burn/blast wound infections. GlobeNewswire Inc

Mar 16, 2021

08:33AM EDT Arch Biopartners Receives Health Canada Authorization to Amend GlobeNewswire Inc

Mar 4, 2021

08:33AM EST ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of GlobeNewswire Inc

Feb 26, 2021

08:43AM EST Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide GlobeNewswire Inc

Feb 2, 2021

07:56AM EST Arch Biopartners Receives Ethics Committee Approval in Turkey to GlobeNewswire Inc

Jan 5, 2021

07:50AM EST University of Calgary Joins the Phase II Trial of LSALT Peptide GlobeNewswire Inc

Dec 15, 2020

12:52PM EST -- Government of Canada contribution up to $6.7 Million -- Funding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of Canadas Plan to Mobilize Science to fight COVID-19 -- Metablok is a novel Canadian drug candidate designed to prevent organ inflammation, which occurs in severe cases of COVID-19 GlobeNewswire Inc

Dec 10, 2020

07:27AM EST VA San Diego Healthcare System Joins the Phase II Trial of LSALT GlobeNewswire Inc

Oct 16, 2020

07:00AM EDT Arch Biopartners Inc. (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19. GlobeNewswire Inc

Oct 7, 2020

07:58AM EDT Arch Biopartners Inc. (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Ministry of Health to proceed with the Phase II trial of its lead drug LSALT peptide (Metablok), targeting acute lung injury and acute kidney injury caused by inflammation in patients with moderate to severe cases of COVID-19. GlobeNewswire Inc

Sep 1, 2020

08:00AM EDT Arch Biopartners Announces Application to the Turkish Ministry of GlobeNewswire Inc

Aug 21, 2020

08:00AM EDT Arch Biopartners Inc. (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) announced it has obtained eligibility with The Depository Trust Company (DTC) in the United States, increasing access for U.S. investors for its common shares listed on the OTCQB. GlobeNewswire Inc

Aug 7, 2020

11:35AM EDT Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session GlobeNewswire Inc

Aug 4, 2020

08:01AM EDT Arch Biopartners Inc. (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received independent Institutional Review Board (IRB) approval for the Phase II trial of its lead drug LSALT peptide (Metablok) targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19. GlobeNewswire Inc

Jul 28, 2020

08:14AM EDT Broward Health Medical Center Becomes First Clinical Site in U.S. GlobeNewswire Inc

Jul 14, 2020

07:00AM EDT Arch Biopartners Engages Global CRO to Conduct LSALT peptide GlobeNewswire Inc

Share